Brief: Onxeo grants exclusive worldwide license for Validive to Monopar Therapeutics

Valerio Therapeutics SA

13/09/2017 07:01

Sept 13 (Reuters) - ONXEO SA  C4X.PA : 
    * ONXEO GRANTS EXCLUSIVE WORLDWIDE LICENSE OF VALIDIVE 
DEVELOPED FOR THE TREATMENT OF ORAL SEVERE MUCOSITIS TO MONOPAR 
THERAPEUTICS 
    * AGREEMENT INCLUDES SUBSTANTIAL MILESTONE PAYMENTS UP TO 
$108M AS WELL AS ESCALATING ROYALTIES ON FUTURE SALES 
    * MONOPAR THERAPEUTICS WILL DRIVE AND FUND ALL REMAINING 
DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES 
    * ONXEO IS ENTITLED TO AN IMMEDIATE $1.0M LICENSE FEE AND 
TO FUTURE MILESTONE PAYMENTS THAT COULD REACH UP TO $108M 
SUBJECT TO ACHIEVEMENT OF AGREED UPON MILESTONES 
    * FUTURE MILESTONE PAYMENTS THAT COULD REACH UP TO $108M 
SUBJECT TO ACHIEVEMENT OF AGREED UPON MILESTONES 
    * ESCALATING ROYALTIES ON SALES UP TO A 2-DIGIT PERCENTAGE 
ARE ALSO PART OF AGREEMENT. 
    * FUTURE MILESTONE PAYMENTS THAT COULD REACH UP TO $108M 
INCLUDING $15.5M RELATED TO REGULATORY MILESTONES, FROM PHASE 
III TO REGISTRATION 
 
Source text for Eikon:  ID:nBw7FVyxKa  
Further company coverage:  C4X.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))